Literature DB >> 16297434

Neurotransmitter deficits in behavioural and psychological symptoms of Alzheimer's disease.

Alessia Lanari1, Francesco Amenta, Giorgio Silvestrelli, Daniele Tomassoni, Lucilla Parnetti.   

Abstract

Behavioural and psychological symptoms of dementia (BPSD) occur in 50-90% of Alzheimer's disease (AD) patients. Imbalance of different neurotransmitters (acetylcholine, dopamine, noradrenaline and serotonin), involvement of specific brain regions responsible for emotional activities (parahippocampal gyrus, dorsal raphe and locus coeruleus) and cortical hypometabolism have been proposed as neurobiological substrate of BPSD. Compared to with respect to the neurochemical component, the cholinergic dysfunction seems to play a major role in contributing to BPSD occurrence. This view is also supported by the findings of recent trials with cholinesterase inhibitors, showing that these drugs are effective in controlling and/or improving BPSD, independent on effects on cognitive dysfunction. On the site of psychotropic drugs, atypical or novel antipsychotics represent the reference drugs for treating BPSD, whereas classic antipsychotic drugs for their profile and the potential side effects should be avoided.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16297434     DOI: 10.1016/j.mad.2005.09.016

Source DB:  PubMed          Journal:  Mech Ageing Dev        ISSN: 0047-6374            Impact factor:   5.432


  45 in total

Review 1.  APP transgenic mice for modelling behavioural and psychological symptoms of dementia (BPSD).

Authors:  R Lalonde; K Fukuchi; C Strazielle
Journal:  Neurosci Biobehav Rev       Date:  2012-02-21       Impact factor: 8.989

2.  Effects of cholinesterase inhibitor on brain activation in Alzheimer's patients measured with functional near-infrared spectroscopy.

Authors:  Florian G Metzger; Ann-Christine Ehlis; Florian B Haeussinger; Andreas J Fallgatter; Katja Hagen
Journal:  Psychopharmacology (Berl)       Date:  2015-09-11       Impact factor: 4.530

3.  High precision liquid chromatography analysis of dopaminergic and serotoninergic responses to acute alcohol exposure in zebrafish.

Authors:  Diptendu Chatterjee; Robert Gerlai
Journal:  Behav Brain Res       Date:  2009-06-08       Impact factor: 3.332

4.  Genetic variation in the alpha 7 nicotinic acetylcholine receptor is associated with delusional symptoms in Alzheimer's disease.

Authors:  Robyn Carson; David Craig; Dominic Hart; Stephen Todd; Bernadette McGuinness; Janet A Johnston; Francis A O'Neill; Craig W Ritchie; A Peter Passmore
Journal:  Neuromolecular Med       Date:  2008-08-12       Impact factor: 3.843

5.  Galanthamine plus estradiol treatment enhances cognitive performance in aged ovariectomized rats.

Authors:  R B Gibbs; A M Chipman; R Hammond; D Nelson
Journal:  Horm Behav       Date:  2011-08-26       Impact factor: 3.587

Review 6.  Biologic and plastic effects of experimental traumatic brain injury treatment paradigms and their relevance to clinical rehabilitation.

Authors:  Alexandra N Garcia; Mansi A Shah; C Edward Dixon; Amy K Wagner; Anthony E Kline
Journal:  PM R       Date:  2011-06       Impact factor: 2.298

Review 7.  Estrogen therapy and cognition: a review of the cholinergic hypothesis.

Authors:  Robert B Gibbs
Journal:  Endocr Rev       Date:  2009-12-17       Impact factor: 19.871

8.  Pharmacokinetics and dopamine/acetylcholine releasing effects of ginsenoside Re in hippocampus and mPFC of freely moving rats.

Authors:  Jing Shi; Wei Xue; Wen-jie Zhao; Ke-xin Li
Journal:  Acta Pharmacol Sin       Date:  2012-12-03       Impact factor: 6.150

9.  Disruptive behavior as a predictor in Alzheimer disease.

Authors:  Nikolaos Scarmeas; Jason Brandt; Deborah Blacker; Marilyn Albert; Georgios Hadjigeorgiou; Bruno Dubois; Davangere Devanand; Lawrence Honig; Yaakov Stern
Journal:  Arch Neurol       Date:  2007-12

10.  Acetylcholinesterase-inhibiting activity of pyrrole derivatives from a novel marine gliding bacterium, Rapidithrix thailandica.

Authors:  Yutthapong Sangnoi; Oraphan Sakulkeo; Supreeya Yuenyongsawad; Akkharawit Kanjana-opas; Kornkanok Ingkaninan; Anuchit Plubrukarn; Khanit Suwanborirux
Journal:  Mar Drugs       Date:  2008-10-13       Impact factor: 5.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.